Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Inovio Pharmaceuticals
INO
$110M
| $1.19M | ﹤0.01% |
29,958
+18,716
| +166% | +$563K |
|
|
SRRA
2552
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.18M | ﹤0.01% |
86,412
+20,618
| +31% | +$269K |
|
2553
Baytex Energy
BTE
$3.06B
| $1.18M | ﹤0.01% |
811,949
+151,652
| +23% | +$187K |
|
2554
Viemed Healthcare
VMD
$351M
| $1.17M | ﹤0.01% |
187,400
+174,300
| +1,331% | +$1.21M |
|
|
FRAN
2555
DELISTED
Francesca's Holdings Corporation
FRAN
| $1.17M | ﹤0.01% |
113,138
+8,200
| +8% | +$124K |
|
2556
Oramed Pharmaceuticals
ORMP
$184M
| $1.17M | ﹤0.01% |
227,725
+15,800
| +7% | +$59.2K |
|
2557
Nelnet
NNI
$4.54B
| $1.17M | ﹤0.01% |
20,100
-53,831
| -73% | -$3.3M |
|
2558
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
$55.3B
| $1.17M | ﹤0.01% |
+27,800
| New | +$1.11M |
|
|
GFED
2559
DELISTED
Guaranty Federal Bancshares In
GFED
| $1.16M | ﹤0.01% |
46,029
+7,328
| +19% | +$181K |
|
|
ATHX
2560
DELISTED
Athersys, Inc. Common Stock
ATHX
| $1.16M | ﹤0.01% |
37,650
-2,627
| -7% | -$86.1K |
|
|
GRCE
2561
Grace Therapeutics
GRCE
$44.8M
| $1.15M | ﹤0.01% |
9,806
+4,575
| +87% | +$452K |
|
|
BNFT
2562
DELISTED
Benefitfocus, Inc.
BNFT
| $1.15M | ﹤0.01% |
+52,545
| New | +$1.19M |
|
|
SCHV
2563
Schwab US Large-Cap Value ETF
SCHV
$16.3B
| $1.15M | ﹤0.01% |
57,300
+16,800
| +41% | +$326K |
|
|
ZEUS
2564
DELISTED
Olympic Steel
ZEUS
| $1.15M | ﹤0.01% |
+64,000
| New | +$1.02M |
|
|
INVX
2565
Innovex International
INVX
$2.18B
| $1.15M | ﹤0.01% |
24,400
-79,500
| -77% | -$3.64M |
|
2566
Fidelity Total Bond ETF
FBND
$27.3B
| $1.14M | ﹤0.01% |
+22,100
| New | +$1.14M |
|
2567
Atlanticus Holdings
ATLC
$1.54B
| $1.14M | ﹤0.01% |
126,708
+42,107
| +50% | +$333K |
|
2568
Fulgent Genetics
FLGT
$510M
| $1.14M | ﹤0.01% |
88,421
-82,059
| -48% | -$975K |
|
|
FPAY
2569
DELISTED
FlexShopper
FPAY
| $1.14M | ﹤0.01% |
450,595
+168,593
| +60% | +$292K |
|
|
TCDA
2570
DELISTED
Tricida, Inc. Common Stock
TCDA
| $1.14M | ﹤0.01% |
+30,200
| New | +$1.13M |
|
|
RRD
2571
DELISTED
RR Donnelley & Sons Co.
RRD
| $1.14M | ﹤0.01% |
288,566
+220,473
| +324% | +$871K |
|
2572
Acushnet Holdings
GOLF
$5.25B
| $1.13M | ﹤0.01% |
34,700
+23,500
| +210% | +$698K |
|
2573
Fuel Tech
FTEK
$45.6M
| $1.13M | ﹤0.01% |
1,186,238
+52,987
| +5% | +$51K |
|
2574
iShares MSCI Japan ETF
EWJ
$23.1B
| $1.13M | ﹤0.01% |
+19,000
| New | +$1.12M |
|
|
OPOF
2575
DELISTED
Old Point Financial
OPOF
| $1.13M | ﹤0.01% |
40,935
+2,300
| +6% | +$61.6K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.